Creative Planning’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.75M Buy
29,398
+4,051
+16% +$506K ﹤0.01% 1410
2025
Q4
$3.09M Buy
25,347
+3,164
+14% +$363K ﹤0.01% 1365
2025
Q3
$2.22M Sell
22,183
-9,149
-29% -$824K ﹤0.01% 1463
2025
Q2
$2.6M Buy
31,332
+348
+1% +$27.8K ﹤0.01% 1124
2025
Q1
$2.51M Buy
30,984
+1,567
+5% +$140K ﹤0.01% 1037
2024
Q4
$2.65M Buy
29,417
+303
+1% +$29.4K ﹤0.01% 969
2024
Q3
$2.88M Buy
29,114
+3,920
+16% +$385K ﹤0.01% 883
2024
Q2
$2.34M Sell
25,194
-1,008
-4% -$90.4K ﹤0.01% 925
2024
Q1
$2.49M Buy
26,202
+1,668
+7% +$155K ﹤0.01% 881
2023
Q4
$2.19M Sell
24,534
-523
-2% -$38.8K ﹤0.01% 889
2023
Q3
$1.83M Buy
25,057
+3,285
+15% +$262K ﹤0.01% 887
2023
Q2
$1.81M Buy
21,772
+999
+5% +$83.5K ﹤0.01% 868
2023
Q1
$1.58M Buy
20,773
+135
+0.7% +$11.2K ﹤0.01% 879
2022
Q4
$1.71M Buy
20,638
+8,454
+69% +$684K ﹤0.01% 808
2022
Q3
$966K Sell
12,184
-7,344
-38% -$619K ﹤0.01% 983
2022
Q2
$1.45M Sell
19,528
-15,675
-45% -$1.18M ﹤0.01% 817
2022
Q1
$3.16M Buy
35,203
+2,233
+7% +$206K ﹤0.01% 579
2021
Q4
$3.69M Sell
32,970
-202
-0.6% -$24.4K 0.01% 501
2021
Q3
$4.17M Sell
33,172
-330
-1% -$42.5K 0.01% 455
2021
Q2
$4.54M Sell
33,502
-2,091
-6% -$275K 0.01% 434
2021
Q1
$4.83M Buy
35,593
+1,957
+6% +$293K 0.01% 423
2020
Q4
$4.74M Sell
33,636
-171
-0.5% -$21.9K 0.01% 390
2020
Q3
$3.77M Sell
33,807
-6,205
-16% -$696K 0.01% 370
2020
Q2
$4.48M Buy
40,012
+6,480
+19% +$638K 0.01% 300
2020
Q1
$2.6M Sell
33,532
-1,377
-4% -$122K 0.01% 361
2019
Q4
$3.32M Sell
34,909
-342
-1% -$29.6K 0.01% 378
2019
Q3
$2.69M Sell
35,251
-360
-1% -$29.9K 0.01% 414
2019
Q2
$3.12M Sell
35,611
-214
-0.6% -$18.3K 0.01% 380
2019
Q1
$3.24M Buy
35,825
+1,038
+3% +$88.3K 0.01% 350
2018
Q4
$2.5M Sell
34,787
-1,631
-4% -$131K 0.01% 376
2018
Q3
$3.49M Sell
36,418
-1,267
-3% -$123K 0.01% 348
2018
Q2
$3.59M Buy
37,685
+499
+1% +$45.9K 0.01% 331
2018
Q1
$3.26M Buy
37,186
+3,492
+10% +$319K 0.01% 342
2017
Q4
$2.86M Buy
33,694
+23,547
+232% +$1.97M 0.01% 366
2017
Q3
$878K Sell
10,147
-1,684
-14% -$135K ﹤0.01% 780
2017
Q2
$913K Buy
11,831
+1,516
+15% +$108K ﹤0.01% 736
2017
Q1
$715K Sell
10,315
-11,972
-54% -$804K ﹤0.01% 805
2016
Q4
$1.32M Buy
22,287
+9,435
+73% +$582K 0.01% 525
2016
Q3
$852K Sell
12,852
-434
-3% -$26.8K 0.01% 661
2016
Q2
$719K Buy
13,286
+4,685
+54% +$257K 0.01% 630
2016
Q1
$444K Sell
8,601
-1,328
-13% -$69K ﹤0.01% 802
2015
Q4
$697K Buy
9,929
+258
+3% +$17.6K 0.01% 621
2015
Q3
$602K Buy
+9,671
New +$762K 0.01% 668
2015
Q2
Sell
-9,813
Closed -$738K 3049
2015
Q1
$738K Buy
9,813
+2,061
+27% +$144K 0.01% 578
2014
Q4
$482K Buy
7,752
+828
+12% +$47.2K 0.01% 710
2014
Q3
$360K Buy
6,924
+2,973
+75% +$152K ﹤0.01% 786
2014
Q2
$203K Buy
3,951
+2,127
+117% +$95.9K ﹤0.01% 1030
2014
Q1
$87K Sell
1,824
-6
-0.3% -$307 ﹤0.01% 1491
2013
Q4
$79K Buy
1,830
+666
+57% +$27.6K ﹤0.01% 1330
2013
Q3
$50K Buy
1,164
+579
+99% +$23.5K ﹤0.01% 1505
2013
Q2
$20K Buy
+585
New +$20.6K ﹤0.01% 1933

Other funds holding XBI

Creative Planning's XBI Position: Q1 2026 in Review

Creative Planning increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, buying an estimated $506K and bringing the position to 29,398 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Creative Planning first reported a position in XBI in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.83M in Q1 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Creative Planning held 29,398 shares of State Street SPDR S&P Biotech ETF worth $3.75M as of Q1 2026.
  • Creative Planning bought 4,051 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $506K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1410 holding.
  • Creative Planning first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 51 quarters since.
  • Creative Planning's State Street SPDR S&P Biotech ETF position peaked at $4.83M in Q1 2021.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.